The Sickle Cell Disease Association of America Medical and Research Advisory Committee has released two statements with updated COVID-19 guidance.

MARAC recommendations are making a minor shift to emphasize a more individualized approach and that people with sickle cell disease should have access to monoclonal antibody (mAbs) treatment according to establish guidelines, to prevent mild COVID from progressing to severe disease. Download the full statements below for more information.

MARAC-COVID-update      MARAC-statement-mAbs.pd